Advertisement

pp 1-24 | Cite as

Pediatric Pharmacotherapy: Anthelminthic Treatment

  • Jill E. WeatherheadEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series

Abstract

Helminths, including nematodes, trematodes, and cestodes, are parasitic worms that infect approximately two billion people worldwide and cause significant morbidity particularly in children. Helminth-induced morbidity is associated with disease burden which typically is greatest in preschool and school-aged children. Preventive chemotherapy through mass drug administration programs has been instituted globally to reduce worm burden and morbidity in children through administration of anthelminthic therapy at regular intervals in helminth endemic areas. Despite these interventions, elimination of these infections remains elusive due to high rates of reinfection and concern for emerging anthelminthic resistance. Although children harbor the greatest burden of disease, minimal pharmacokinetic, safety, and tolerability data is available for young children, limiting their use. Novel anthelminthic therapies are critically needed to combat helminth disease with particular attention paid toward medications that can be used in young children to reduce global helminth-induced morbidity.

Keywords

Anthelminthic vaccine Anthelminthics Cestodes Global health Helminths Mass drug administration Nematodes Trematodes 

References

  1. Abdel-Tawab AM, Bradley M, Ghazaly EA et al (2009) Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. Br J Clin Pharmacol 68:737–742.  https://doi.org/10.1111/j.1365-2125.2009.03524.xCrossRefGoogle Scholar
  2. Albonico M (2003) Methods to sustain drug efficacy in helminth control programmes. Acta Trop 86:233–242.  https://doi.org/10.1016/S0001-706X(03)00043-3CrossRefGoogle Scholar
  3. American Academy of Pediatrics (2015) Red book – 2015 report of the Committee on Infectious Diseases, 30th edn. American Academy of Pediatrics, Elk Grove VillageGoogle Scholar
  4. Babes RM, Selescu T, Domocos D, Babes A (2017) The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol Appl Pharmacol 336:55–65.  https://doi.org/10.1016/j.taap.2017.10.012CrossRefGoogle Scholar
  5. Bendavid E, Bogoch II, Lai Y-S et al (2016) Assessment of global guidelines for preventive chemotherapy against schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study. Lancet Infect Dis 16:1065–1075.  https://doi.org/10.1016/s1473-3099(16)30073-1CrossRefGoogle Scholar
  6. Bethony J, Brooker S, Albonico M et al (2006) Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet (London, England) 367:1521–1532.  https://doi.org/10.1016/S0140-6736(06)68653-4CrossRefGoogle Scholar
  7. Centers for Disease Control and Prevention (2013) Progress toward elimination of onchocerciasis in the Americas – 1993-2012. Morb Mortal Wkly Rep 62:405–408Google Scholar
  8. Centers for Disease Control and Prevention (2017) Parasites – loiasis. https://www.cdc.gov/parasites/loiasis/health_professionals/index.html#tx. Accessed 29 May 2019
  9. Chai J-Y (2013) Praziquantel treatment in trematode and cestode infections: an update. J Infect Chemother 45:32–43.  https://doi.org/10.3947/ic.2013.45.1.32CrossRefGoogle Scholar
  10. Clarke NE, Doi SAR, Wangdi K et al (2019) Efficacy of anthelminthic drugs and drug combinations against soil-transmitted helminths: a systematic review and network meta-analysis. Clin Infect Dis 68:96–105.  https://doi.org/10.1093/cid/ciy423CrossRefGoogle Scholar
  11. Crompton DWT, Montresor A, Nesheim MC, Savioli L (2003) Controlling disease due to helminth infections. World Health Organization, GenevaGoogle Scholar
  12. Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21:659–667.  https://doi.org/10.1097/QCO.0b013e328318978fCrossRefGoogle Scholar
  13. Fox LM (2006) Ivermectin: uses and impact 20 years on. Curr Opin Infect Dis 450:588–593Google Scholar
  14. Furtado LFV, de Paiva Bello ACP, Rabelo ÉML (2016) Benzimidazole resistance in helminths: from problem to diagnosis. Acta Trop 162:95–102Google Scholar
  15. GBD (2017) Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease study 201. Lancet 390:1260–1344.  https://doi.org/10.1016/S0140-6736(17)32130-XCrossRefGoogle Scholar
  16. Groups AP, Hotez PJ, Strych U et al (2016) Efficacy and reinfection with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole. Parasit Vectors 9:123.  https://doi.org/10.1186/s13071-016-1406-8CrossRefGoogle Scholar
  17. Hotez P (2016) Blue marble health: an innovative plan to fight diseases of the poor amid wealth. Johns Hopkins University Press, BaltimoreGoogle Scholar
  18. Hotez PJ, Bundy DAP, Beegle K et al (2006) Helminth infections: soil-transmitted helminth infections and schistosomiasis. In: Jamison D, Breman J, Measham A et al (eds) Disease control priorities in developing countries, 2nd edn. The World Bank, WashingtonGoogle Scholar
  19. Hotez PJ, Strych U, Lustigman S, Bottazzi ME (2016) Human anthelminthic vaccines: rationale and challenges. Vaccine 34:3549–3555Google Scholar
  20. Humphries D, Nguyen S, Kumar S et al (2017) Effectiveness of albendazole for hookworm varies widely by community and correlates with nutritional factors: a cross-sectional study of school-age children in Ghana. Am J Trop Med Hyg 96:347–354.  https://doi.org/10.4269/ajtmh.16-0682CrossRefGoogle Scholar
  21. Huwyler J, Moser W, Yapi RB et al (2017) Efficacy and safety of tribendimidine, tribendimidine plus ivermectin, tribendimidine plus oxantel pamoate, and albendazole plus oxantel pamoate against hookworm and concomitant soil-transmitted helminth infections in Tanzania and Côte d’Ivoire: a randomised, controlled, single-blinded, non-inferiority trial. Lancet Infect Dis 17:1162–1171.  https://doi.org/10.1016/s1473-3099(17)30487-5CrossRefGoogle Scholar
  22. Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG (2018) Soil-transmitted helminth infections. Lancet 391:252–265.  https://doi.org/10.1016/S0140-6736(17)31930-XCrossRefGoogle Scholar
  23. Kabuyaya M, Chimbari MJ, Mukaratirwa S (2018) Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in sub-Saharan Africa: a systematic review. Infect Dis Poverty. 7:73Google Scholar
  24. Kang G, Bethony JM, Behnke JM et al (2011) Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis 5:e948.  https://doi.org/10.1371/journal.pntd.0000948CrossRefGoogle Scholar
  25. Kelley J, Elliott T, Beddoe T et al (2016) Current threat of triclabendazole resistance in Fasciola hepatica. Trends Parasitol 32:458–469Google Scholar
  26. Köhler P (2001) The biochemical basis of anthelmintic action and resistance. Int J Parasitol 31:336–345.  https://doi.org/10.1016/S0020-7519(01)00131-XCrossRefGoogle Scholar
  27. Kopp SR, Kotze AC, McCarthy JS, Coleman GT (2007) High-level pyrantel resistance in the hookworm Ancylostoma caninum. Vet Parasitol 143:299–304.  https://doi.org/10.1016/j.vetpar.2006.08.036CrossRefGoogle Scholar
  28. Lacey E (1990) Mode of action of benzimidazoles. Parasitol Today 6:112–115.  https://doi.org/10.1016/0169-4758(90)90227-UCrossRefGoogle Scholar
  29. Laing R, Gillan V, Devaney E (2017) Ivermectin – old drug, new tricks? Trends Parasitol 33:463–472.  https://doi.org/10.1016/j.pt.2017.02.004CrossRefGoogle Scholar
  30. Li S, Gankpe FG, Wilner LB et al (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet 392:1789–1858.  https://doi.org/10.1016/s0140-6736(18)32279-7CrossRefGoogle Scholar
  31. The Medical Letter (2013) Drugs for parasitic infections. 11:e1–e31Google Scholar
  32. Mejia R, Nutman TB (2012) Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 25:458–463.  https://doi.org/10.1097/QCO.0b013e3283551dbdCrossRefGoogle Scholar
  33. Montresor A, Awasthi S, Crompton DWT (2003) Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. Acta Trop 86:223–232.  https://doi.org/10.1016/S0001-706X(03)00042-1CrossRefGoogle Scholar
  34. Moon TD, Oberhelman RA (2005) Antiparasitic therapy in children. Pediatr Clin N Am 52:917–948.  https://doi.org/10.1016/j.pcl.2005.02.012CrossRefGoogle Scholar
  35. Moser W, Ali SM, Ame SM et al (2016) Efficacy and safety of oxantel pamoate in school-aged children infected with Trichuris trichiura on Pemba Island, Tanzania: a parallel, randomised, controlled, dose-ranging study. Lancet Infect Dis 16:53–60.  https://doi.org/10.1016/S1473-3099(15)00271-6CrossRefGoogle Scholar
  36. Moser W, Schindler C, Keiser J (2017) Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ 358:4307.  https://doi.org/10.1136/bmj.j4307CrossRefGoogle Scholar
  37. Moser W, Sayasone S, Xayavong S et al (2018) Efficacy and tolerability of triple drug therapy with albendazole, pyrantel pamoate, and oxantel pamoate compared with albendazole plus oxantel pamoate, pyrantel pamoate plus oxantel pamoate, and mebendazole plus pyrantel pamoate and oxantel pamoate against hookworm infections in school-aged children in Laos: a randomised, single-blind trial. Lancet Infect Dis 18:729–737.  https://doi.org/10.1016/S1473-3099(18)30220-2CrossRefGoogle Scholar
  38. Mutapi F (2015) Changing policy and practice in the control of pediatric schistosomiasis. Pediatrics. 135:536–544.  https://doi.org/10.1542/peds.2014-3189CrossRefGoogle Scholar
  39. Nabarro LE, Amin Z, Chiodini PL (2015) Current management of cystic echinococcosis: a survey of specialist practice. Clin Infect Dis 60:721–728.  https://doi.org/10.1093/cid/ciu931CrossRefGoogle Scholar
  40. Olds GR (2003) Administration of praziquantel to pregnant and lactating women. Acta Trop 86:185–195Google Scholar
  41. Osei-Atweneboana MY, Awadzi K, Attah SK et al (2011) Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis 5:1–11.  https://doi.org/10.1371/journal.pntd.0000998CrossRefGoogle Scholar
  42. Panic G, Duthaler U, Speich B, Keiser J (2014) Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist 4:185–200.  https://doi.org/10.1016/j.ijpddr.2014.07.002CrossRefGoogle Scholar
  43. Peixoto CA, Silva BS (2014) Anti-inflammatory effects of diethylcarbamazine: a review. Eur J Pharmacol 734:35–41Google Scholar
  44. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ (2014) Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. Parasit Vectors 7:37.  https://doi.org/10.1186/1756-3305-7-37CrossRefGoogle Scholar
  45. Ramanathan R, Nutman T (2008) Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 10:105–110.  https://doi.org/10.1007/S11908-008-0019-6CrossRefGoogle Scholar
  46. Reynoldson JA, Behnke JM, Pallant LJ et al (1997) Failure of pyrantel in treatment of human Hookworm infections (Ancylostoma duodenale) in the Kimberley region of North West Australia. Acta Trop.  https://doi.org/10.1016/S0001-706X(97)00106-XGoogle Scholar
  47. Robertson AP, Puttachary S, Buxton SK, Martin RJ (2015) Tribendimidine: mode of action and nAChR subtype selectivity in Ascaris and Oesophagostomum. PLoS Negl Trop Dis 9:e0003495.  https://doi.org/10.1371/journal.pntd.0003495CrossRefGoogle Scholar
  48. Skinner-Adams TS, Sumanadasa SDM, Fisher GM et al (2016) Defining the targets of antiparasitic compounds. Drug Discov Today 21:725–739.  https://doi.org/10.1016/j.drudis.2016.01.002CrossRefGoogle Scholar
  49. Sousa-Figueiredo JC, Betson M, Atuhaire A et al (2012) Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis 6.  https://doi.org/10.1371/journal.pntd.0001864Google Scholar
  50. Speich B, Ame SM, Ali SM et al (2014) Oxantel Pamoate–Albendazole for Trichuris trichiura infection. N Engl J Med 370:610–620.  https://doi.org/10.1056/NEJMoa1301956CrossRefGoogle Scholar
  51. Stothard JR, Sousa-Figueiredo JC, Betson M et al (2013) Schistosomiasis in African infants and preschool children: let them now be treated! Trends Parasitol 29:197–205.  https://doi.org/10.1016/j.pt.2013.02.001CrossRefGoogle Scholar
  52. Urbani C, Albonico M (2003) Anthelminthic drug safety and drug administration in the control of soil-transmitted helminthiasis in community campaigns. Acta Trop 86:215–221.  https://doi.org/10.1016/S0001-706X(03)00036-6CrossRefGoogle Scholar
  53. US Food and Drug Administration Prescribing Information Albenza. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf. Accessed 3 May 2017
  54. Walker M, Mabud TS, Olliaro PL et al (2016) New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel. Parasit Vectors 9:41.  https://doi.org/10.1186/s13071-016-1312-0CrossRefGoogle Scholar
  55. Weatherhead JE, Hotez PJ (2015) Worm infections in children. Pediatr Rev 36:341–352.  https://doi.org/10.1542/pir.36-8-341CrossRefGoogle Scholar
  56. Weatherhead JE, Hotez PJ, Mejia R (2017) The global state of helminth control and elimination in children. Pediatr Clin N Am 64.  https://doi.org/10.1016/j.pcl.2017.03.005Google Scholar
  57. Weeks JC, Roberts WM, Leasure C et al (2018) Sertraline, paroxetine, and chlorpromazine are rapidly acting anthelmintic drugs capable of clinical repurposing. Sci Rep 8:1–17.  https://doi.org/10.1038/s41598-017-18457-wCrossRefGoogle Scholar
  58. Weng HB, Chen HX, Wang MW (2018) Innovation in neglected tropical disease drug discovery and development. Infect Dis Poverty 7:1–9.  https://doi.org/10.1186/s40249-018-0444-1CrossRefGoogle Scholar
  59. White AC, Coyle CM, Rajshekhar V et al (2018) Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 98:945–966.  https://doi.org/10.4269/ajtmh.18-88751CrossRefGoogle Scholar
  60. World Health Organization (1995) WHO model prescribing information: drugs used in parasitic diseases, 2nd edn. World Health OrganizationGoogle Scholar
  61. World Health Organization (2002) Report of the WHO informal consultation on the use of praziquantel during pregnancy/lactation and albendazole/mebendazole in children under 24 monthsGoogle Scholar
  62. World Health Organization (2006) Preventive chemotherapy in human helminthiasis: coordinated use of anthleminthic drugs in control interventionsGoogle Scholar
  63. World Health Organization (2013) Schistosomiasis: control report 2001–2011 and strategic plan 2012–2020Google Scholar
  64. World Health Organization (2016) Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasisGoogle Scholar
  65. World Health Organization (2017a) Guideline: preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groupsGoogle Scholar
  66. World Health Organization (2017b) Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. World Health OrganizationGoogle Scholar
  67. Wu V-C, Huang J-W, Lien H-C et al (2006) Levamisole-induced multifocal inflammatory leukoencephalopathy. Medicine (Baltimore) 85:203–213.  https://doi.org/10.1097/01.md.0000230250.95281.60CrossRefGoogle Scholar
  68. Zaha O, Hirata T, Kinjo F et al (2002) Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother 8:94–98.  https://doi.org/10.1007/s101560200013CrossRefGoogle Scholar
  69. Zheng R (1995) Differential diagnosis of delayed encephalopathy induced by anthelmintic imidazoles. Zhonghua Nei Ke Za Zhi 34:468–471Google Scholar
  70. Zwang J, Olliaro P (2017) Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. Parasit Vectors:1–16.  https://doi.org/10.1186/s13071-016-1958-7
  71. Zwang J, Olliaro PL (2018) Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis – a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 8:e3286.  https://doi.org/10.1371/journal.pntd.0003286CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pediatrics, Section of Tropical MedicineBaylor College of MedicineHoustonUSA
  2. 2.National School of Tropical Medicine, Baylor College of MedicineHoustonUSA
  3. 3.Department of Medicine, Section of Infectious DiseasesBaylor College of MedicineHoustonUSA

Personalised recommendations